Clinical trial
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2…
NCT00328965 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00328965 |
|---|---|
| Title | Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea |
| Official title | An Open Label, Multi-centre, Single Arm Phase IV Study to Evaluate the Antihypertensive Effect of Lacidipine in Mild to Moderate Essential Hypertension Patients With Type 2 Diabetes in Korea |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2, Essential Hypertension |
| Intervention type | Drug |
| Interventions | Lacidipine |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | May 24, 2006 |
| Last update posted | Aug 16, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: